Document is current

Article History

Received: 6 June 2025

Accepted: 31 July 2025

First Online: 12 November 2025

Declarations

:

: Ethics approval was granted by the South Central—Berkshire Research Ethics Committee 2nd August 2023. Substantial amendment 01 was an administrative change approved 22nd August 2023. Substantial amendment 02 included a protocol update to version 2.0, main changes were the addition of prescription guidance to clarify that prescription can be issued by primary care via shared care agreement and change of the SWAT primary outcome from patients randomised to patients consented. This amendment also included a new patient letter/email for sending vouchers and was approved 5th July 2024. Substantial amendment 03 included a new advertising postcard and poster update and was approved 1 st Nov 2024.The process for obtaining participant informed consent will be in accordance with the REC guidance, and GCP and any other regulatory requirements that might be introduced. The investigator or their nominee and the participant shall both sign and date the Consent Form before the person can participate in the trial.

: Not applicable, no identifying images or personal or clinical details of participants are presented here or will be presented in the trial results. Informed consent materials are available from the author on request.

: The authors and PIs declare that they have no competing interests.